Immunologically active phenotype by gene expression profiling is associated with clinical benefit from PD-1/PD-L1 inhibitors in real-world head and neck and lung cancer patients

Jean‐Philippe Foy, Andy Karabajakian, Sandra Ortiz‐Cuaran, Maxime Boussageon, Lucas Michon, Jebrane Bouaoud, Dorssafe Fekiri, Marie Robert, Kim-Arthur Baffert, G. Hervé, Pauline Quilhot, Valéry Attignon, Angélique Girod, André Chaine, Mourad Benassarou, Philippe Zrounba, Christophe Caux, François Ghiringhelli, Sylvie Lantuéjoul, Carole Crozes, Isabelle Brochériou, M. Pérol, Jérôme Fayette, Chloé Bertolus, Pierre Saintigny